A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).

被引：5

作者：

Abali, Huseyin

Yalcin, Suayib

Onal, Huseyin Cem

Dane, Faysal

Oksuzoglu, Berna

Ozdemir, Nuriye

Mertsoylu, Huseyin

Artac, Mehmet

Camci, Celalettin

Karabulut, Bulent

Basal, Fatma Bugdayci

Budakoglu, Burcin

Sendur, Mehmet Ali Nahit

Goktas, Burce

Ozdener, Fatih

Calisgan, Arzu

机构：

[1] Acibadem Univ, Adana, Turkey

[2] Hacettepe Univ, Ankara, Turkey

[3] Baskent Univ, Radiat Oncol, Adana, Turkey

[4] Marmara Univ, Istanbul, Turkey

[5] Dr Abdurrahman Yurtaslan Ankara Onkol Training &, Ankara, Turkey

[6] Ankara Numune Training & Res Hosp, Ankara, Turkey

[7] Baskent Univ, Adana, Turkey

[8] Necmettin Erbakan Univ, Meram Sch Med, Konya, Turkey

[9] Gaziantep Univ, Gaziantep, Turkey

[10] Ege Univ, Izmir, Turkey

[11] Yildirim Beyazit Univ, Fac Med, Dept Med Oncol, Ankara, Turkey

[12] Roche Pharmaceut, Istanbul, Turkey

[13] Medstats Consulting, Istanbul, Turkey

来源：

关键词：

D O I：

10.1200/jco.2016.34.4_suppl.tps182

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS182

引用

页数：1